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Key Points
• The STAT3b/a mRNA
expression ratio in AML
patients is a favorable
prognostic marker and
positively correlates
with overall survival.
• Transgenic Stat3b ex-
pression delays disease
progression and pro-
longs overall survival in
AML mouse models.
Signal transducer and activator of transcription 3 (STAT3) exists in 2 alternatively spliced
isoforms, STAT3a and STAT3b. Although truncated STAT3b was originally postulated to
act as a dominant-negative form of STAT3a, it has been shown to have various STAT3a-
independent regulatory functions. Recently, STAT3b gained attention as a powerful
antitumorigenic molecule in cancer. Deregulated STAT3 signaling is often found in acute
myeloid leukemia (AML); however, the role of STAT3b in AML remains elusive. Therefore,
we analyzed the STAT3b/amessenger RNA (mRNA) expression ratio in AML patients, where
we observed that a higher STAT3b/amRNA ratio correlated with a favorable prognosis and
increased overall survival. To gain better understanding of the function of STAT3b in AML,
we engineered a transgenic mouse allowing for balanced Stat3b expression. Transgenic
Stat3b expression resulted in decelerated disease progression and extended survival in
PTEN- and MLL-AF9–dependent AML mouse models. Our ﬁndings further suggest that the
antitumorigenic function of STAT3b depends on the tumor-intrinsic regulation of a small set
of signiﬁcantly up- and downregulated genes, identiﬁed via RNA sequencing. In conclusion,
we demonstrate that STAT3b plays an essential tumor-suppressive role in AML.
Introduction
Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor in cell
proliferation, maturation, and survival and hence involved in several oncogenic pathways. Although
STAT3 is most commonly described as an oncogene in cancer, evidence also shows its role as
a tumor suppressor.1-8 This opposing role of STAT3 in cancer depends considerably on its expression
as different isoforms.1,9 Alternative splicing gives rise to full-length STAT3a and truncated STAT3b.
STAT3b variants lack the canonical STAT3 C-terminus and instead contain 7 unique amino acids,
resulting in enhanced DNA binding affinity.10 Both isoforms are ubiquitously expressed; however,
although the loss of STAT3a leads to embryonic lethality in mice, STAT3b is not required for viability.11
Accordingly, STAT3b was originally described as a dominant-negative regulator of STAT3.10,12,13
Despite that, several studies have postulated an active regulatory role for STAT3b and identified
a large number of STAT3b-specific target genes.11,13-16 Recently, STAT3b has gained attention as
a powerful antitumorigenic molecule, as shown for melanoma, esophageal squamous cell carcinoma,
and breast, lung, and colon cancers.17-24
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STAT3 has been shown to be constitutively active in AML cell
lines and patients, causing a proliferative advantage and apoptosis
protection.25-28 In addition, STAT3 activity has been associated
with short disease-free survival in a subset of AML patients.29-32 As
a consequence, STAT3 became an attractive therapeutic target
in AML, but results from early clinical studies with STAT3 inhibitors
have shown moderate effectiveness.28,33-35 In contrast to these
studies, Redell et al36 described a protective role of increased
STAT3 phosphorylation upon cytokine stimulation in AML patients,
correlating with high disease-free survival. These conflicting results
in AMLmight indicate that the impact of STAT3 inhibition in different
patient subsets can vary as a result of its heterogeneous biological
context.37
An improved understanding of the biological functions of STAT3
isoforms in AML is therefore required. Here, we conducted
an extensive study regarding the specific role of STAT3b in AML.
We found that the balance of STAT3 isoform expression in AML
patients can serve as a favorable prognostic tool. Furthermore, we
demonstrate that the transgenic expression of STAT3b impairs
leukemia progression. Taken together, our data identify STAT3b
as a novel tumor suppressor in AML.
Patients and methods
AML patients
This study was approved by the ethics committees of the Medical
Universities of Graz and Vienna (Austria) and conducted accord-
ing to the Declaration of Helsinki. Written informed consent was
obtained. Diagnostic peripheral blood (PB) and bone marrow
(BM) samples from AML patients were enriched for mononuclear
cells using Ficoll (GE Healthcare, Milan, Italy) density-gradient
centrifugation before freezing in fetal bovine serum (Gibco; Thermo
Fisher Scientific, Waltham, MA) with 10% dimethyl sulfoxide
(Sigma Aldrich, St. Louis, MO), as previously described.38 All
samples contained .80% blast cells after enrichment. Healthy
CD341 hematopoietic stem and progenitor cells (HSPCs) were
collected from umbilical cord blood and enriched by magnetic-
activated cell sorting (Miltenyi Biotech, Gladbach, Germany).
Cytogenetic risk stratification of patients into favorable, intermedi-
ate, and adverse subgroups was applied according to the Medi-
cal Research Council classification scheme.39 In a proportion of
patients, information on the mutational status of the FLT3, NPM1,
and CEBPA genes was available. Only patients receiving treatment
with curative intention (chemotherapy with or without allogeneic
hematopoietic stem cell transplantation) were included in the
analysis of overall survival as defined by the European LeukemiaNet
2017 guidelines.40 In accordance with literature describing an
association of oncogenic FLT3 mutations with JAK/STAT activity,
primarily STAT5 and STAT3, we furthermore excluded patients with
a confirmed FLT3 mutation in survival analysis.41-46
Generation of Stat3b transgenic mice
A Stat3b expression cassette containing the CAGGS promoter,
a loxP-flanked (floxed) transcriptional/translational stop cassette,
N-terminus FLAG-tagged Stat3b mouse complementary DNA
(cDNA), internal ribosomal entry site (IRES)/yellow fluorescent
protein (YFP), and a bovine growth hormone–derived polyadeny-
lation signal flanked by attB sites was assembled by conven-
tional cloning. The Stat3b expression cassette was integrated into
a bacterial artificial chromosome (BAC) containing the Rosa26
locus (RP24-85L15) by PhiC31 integrase–mediated cassette
exchange.47 Rosa26-modified BAC DNA was purified48 and
microinjected into the pronucleus of C57BL/6 oocytes.
Animal studies
Animal experiments were approved by the Animal Ethics Committee
of the Medical University of Vienna and the Austrian Federal
Ministry of Education, Science and Research. Mice were bred and
kept under pathogen-free conditions at the Institute of Pharmacol-
ogy, Medical University of Vienna (Vienna, Austria). Stat3b trans-
genic (Stat3bTG) mice were crossbred with Mx1-Cre recombinase
transgenic (MxCre) floxed Pten mice.49,50 To induce Cre, animals
were intraperitoneally injected with 100 mL of polyinosine-polycytidine
(pIpC; 2 mg/mL; Sigma Aldrich) at the age of 5 to 7 weeks on 3
consecutive days.
Transplantation of FLCs
Fetal liver cells (FLCs) were isolated from Stat3bTG and wild-type
(wt) mice at embryonic day 13.5, genotyped, and frozen in fetal
bovine serum with 10% dimethyl sulfoxide. Platinum E cells were
transfected by calcium phosphate coprecipitation with the pMSCV-
MLL-AF9-IRES-Venus vector. FLCs were thawed 1 day before
infection. Cells were spinoculated (1000g for 90 minutes) with
retroviral supernatant in the presence of 10 mg/mL of polybrene
(Sigma Aldrich). After 24 hours, 2 3 106 FLCs were injected into
immunocompromised NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (The Jack-
son Laboratory, Bar Harbor, ME) mice via the tail vein. Infection
rates for MLL-AF9/Venus1 (Venus1) cells ranged from 7% to 12%.
Four weeks after transplantation, mice were injected with pIpC, as
described in “Animal studies.”
Statistics
Patient data. STAT3b/a messenger RNA (mRNA) ratio
values were compared between groups using the Kruskal-Wallis
test followed by pairwise comparisons corrected for multiplicity
by Dunn’s method. To test the association between the STAT3b/
a mRNA ratio and survival of patients with AML, a multivariable
Cox regression model was used. In addition to the logSTAT3b/
a ratio as a continuous variable, the model included and thus
corrected for established AML risk parameters: patient age at
diagnosis, percentage of blasts of all white blood cells (WBCs),
and cytogenetic risk group as categorical predictor. To show the
effect of logSTAT3b/a ratio on the survival function, it was plotted
once for the maximally observed ratio, once for the median, and
once for the lowest observed ratio. To visualize the change in
hazard ratio (HR) associated with a certain STAT3b/a ratio
change, it was calculated relative to the estimated survival at the
median STAT3b/a ratio using Exp(B) and its 95% confidence
interval.
Animal and cellular data. Data were analyzed using log-
rank Student t tests (Mantel Cox), Student t tests, and 1-way
analyses of variance in combination with Tukey’s multiple
comparison post hoc test. Error bars represent means6 standard
deviations. P , .05 was regarded as statistically significant.
P values are indicated as follows: *P , .05, **P , .01, and
***P , .001. The absence of a P value or asterisk indicates
nonsignificance. Additional methods are provided in the supple-
mental material.
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Results
Higher ratio of STAT3b/a mRNA expression
correlates with favorable clinical prognosis and
prolonged survival in AML patients
Differential expression of STAT3 isoforms has been observed in
AML patients, but whether their role is of oncogenic or tumor-
suppressive nature is incompletely understood.29-32 We obtained
diagnostic samples from 94 AML patients (supplemental Table 1)
and analyzed mRNA expression of STAT3 isoforms in compar-
ison with HSPCs from 8 healthy donors. The mRNA expression
of total STAT3, STAT3a, and especially STAT3b differed
between leukemic blasts and healthy HSPCs. We found
significantly decreased mRNA expression levels of STAT3b in
AML samples compared with healthy HSPCs (supplemental
Figure 1A). Next, patients of different cytogenetic risk groups
were compared regarding STAT3 expression levels (supple-
mental Figure 1B). Strikingly, we found that the STAT3b/a
mRNA expression ratio in AML samples was significantly lower
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Figure 1. A higher STAT3b/a mRNA ratio correlates with clinical prognosis and survival in AML patients. (A) STAT3b/a mRNA ratio (normalized to b-ACTIN) in
AML patients (n 5 94) and HSPCs from healthy controls (n 5 8), and STAT3b/a mRNA ratio in AML patients with a favorable (n 5 23), intermediate (n 5 22), or adverse
(n 5 49) prognosis. Data were compared using the Student t test and Kruskal-Wallis test. (B) Kaplan-Meier plot showing the survival of patients with a STAT3b/a mRNA ratio
in the highest, medium, or lowest tertile (n 5 48). (C) Estimated survival functions resulting from multivariable Cox regression. In addition to the logSTAT3b/a mRNA ratio in its
continuous form, the model includes and thus adjusts for patient age, blast count, and cytogenetic risk category at diagnosis. For illustrative purposes, curves were plotted for
the maximal, median, and minimal observed STAT3b/a mRNA ratios. The model P value refers to the hypothesis that all variables in the model collectively predict survival; the
logSTAT3b/a mRNA P value tests whether the ratio predicts survival independent of other variables. Of note, the estimated survival changes continuously with the STAT3b/a
mRNA ratio. Therefore, the survival can be plotted for any STAT3b/a mRNA ratio value. To visualize the magnitude of survival difference between the maximally observed
(0.034) and the minimally observed (0.002), we plotted survival function for these values and for the median value as reference. Modeling the effect of STAT3b/a mRNA ratio
in its continuous form allowed avoidance of arbitrary groups. (D) Change of estimated HR (thick line) with 95% confidence interval (CI; dashed lines) associated with different
STAT3b/a mRNA ratio levels. The median STAT3b/a mRNA ratio was chosen as reference, not affecting the statistical analysis. The curve was plotted for a range of
STAT3b/a mRNA ratios spanning from the minimum to maximum observed ratio. Estimated HRs are given for the upper and lower ends of the curve. *P , .05, ***P , .001.
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than that in healthy HSPCs and that a high STAT3b/a mRNA
ratio correlated with a favorable clinical prognosis (Figure 1A).
Furthermore, we explored the correlation between the STAT3b/
a mRNA ratio in AML patients (n 5 48) and overall survival. A
higher STAT3b/a mRNA ratio was associated with longer over-
all survival in AML patients (Figure 1B) after adjustment for patient
age at diagnosis, percentage of blasts, and cytogenetic risk category
(Figure 1C). A 10-fold increase of the STAT3b/a mRNA ratio was
estimated to be associated with an HR of 0.34 (95% confidence
interval, 0.12-0.95; Figure 1D). Taken together, the STAT3b/a
mRNA ratio correlates with clinical prognosis and survival in AML
patients, arguing for the importance of strict maintenance of balanced
STAT3b/a mRNA expression.
Generation and characterization of a novel Stat3b
transgenic mouse model
To investigate the role of STAT3b, we established a novel mouse
line conditionally expressing murine Stat3b. We chose a BAC
containing the Rosa26 locus, because this has been shown to be
open chromatin and support transgene expression. The construct
for the generation of Stat3bTG mice consisted of a CAGGS
promoter followed by a floxed Stop cassette, FLAG-tagged murine
Stat3b cDNA, and IRES and YFP (Figure 2A). Purified BAC DNA
was microinjected into the pronucleus of C57BL/6 oocytes, and
Stat3bTG mice were identified via Southern blot and genotyping
(supplemental Figure 2A). Conditional expression of the trans-
gene was achieved by crossing Stat3bTG mice with a pIpC-
inducible MxCre mouse line on a C57BL/6 background. The
resulting mice, heterozygous for Cre and the Stat3b transgene
(Stat3bTG), were injected with pIpC, causing the expression of
CRE recombinase and the excision of the Stop cassette and
allowing for the expression of exogenous STAT3b. Ectopic
expression of STAT3b was confirmed in liver and spleen 20 days
postinduction (Figure 2B). YFP was detected in.20% of BMCs
as well as in hematopoietic cell subsets (Figure 2C).
Stat3bTG mice were found to be phenotypically normal before
and after induced Stat3bTG expression (followed up to 12 months
of life; data not shown). WBC count and relative spleen weight
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Figure 2. Generation and characterization of
a Stat3b transgenic mouse model. (A) A schematic
overview of the Stat3b transgene BAC construct. (B)
Total cell lysates from spleen and liver were subjected to
western blot analysis with the indicated antibodies
(STAT3, FLAG, and HSP90). Liver sections stained with
an antibody against FLAG show the expression of
ectopic STAT3b. (C) A representative flow cytometry
analysis of YFP1 BM cells (BMCs) and hematopoietic
cell populations (progenitor: Lin2Sca-11c-Kit2; LSK:
Lin2Sca-11c-Kit1) at day 20 postinduction. Data
(wt vs Stat3bTG) were not statistically compared.
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(normalized to body weight) in Stat3bTG mice were comparable to
those of pIpC-treated wt animals (supplemental Figure 2B). Further-
more, hematopoietic cell populations in BM and spleen were
unaffected by Stat3bTG expression (supplemental Figure 2C). In
accordance, hematoxylin and eosin (H&E) staining of spleen and liver
sections did not reveal any overt abnormalities in organ architecture
or extramedullary hematopoiesis (supplemental Figure 2D).
Elevated expression of STAT3b prolongs survival in
an AML mouse model based on Pten deletion
The impact of STAT3b on AML progression in vivo was investigated
via the homozygous knockout of Pten in the hematopoietic
compartment. Conditional ablation of Pten rapidly induces myelo-
proliferative neoplasms, which develop into secondary AML.49,50
0
0
p=0.0034
50 100
Days
150 200
20
Ov
er
all
 su
rv
iva
l [
%
]
40
60
80
100
Pten/+
Pten/+Stat3TG
Pten/
Pten/Stat3TG
A
Pten/+
Pten/
Pten/Stat3TG
0.00
d10 d20 d30
0.05
0.10
0.15 *
Lin
- Sc
a-
1+
 c-
kit
+ 
ce
lls
 [%
]
0.0
d10 d20 d30
0.1
0.3
0.2
0.4
Spleen
0
d10 d20 d30
10
20
30
40 ** *
Bone Marrow
0
d10 d20 d30
20
CD
11
b+
Gr
-1
+  c
ell
s [
%
]
40
60
80
100
***
*** * *
B
Pten/+ Pten/ Pten/Stat3TG
S
pl
ee
n
Li
ve
r
C
Figure 3. Elevated expression of STAT3b prolongs survival in
an AML mouse model based on Pten deletion. (A) Kaplan-Meier
plot showing the significantly different survival (P 5 .0034) of PtenD/D
(n 5 16) and PtenD/DStat3bTG (n 5 11) mice, with PtenD/1 (n 5 9)
and PtenD/1 Stat3bTG (n 5 11) as controls. (B) Percentages of
myeloid (CD11b1Gr11) and LSK cells in the BM and spleen of
control, PtenD/D, and PtenD/DStat3bTG mice at 10, 20, and 30 days
postinduction (n 5 5 per group). Data (PtenD/1 vs PtenD/D vs
PtenD/DStat3bTG for each time point) were compared using 1-way
analysis of variance. (C) H&E-stained liver and spleen sections of
PtenD/D, PtenD/DStat3bTG, and control mice at day 20 postinduction.
*P , .05, **P , .01, ***P , .001.
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Figure 4. STAT3b impairs colony formation capacity of MLL-AF9–transformed cells. (A) Workflow of FLCs and BMCs harvested from Stat3bTG mice and wt
littermates. MLL-AF9–transformed cells were subsequently used for in vitro analysis and transplantation. (B) Western blot analysis showing STAT3 and phosphorylated STAT3
(pSTAT3) expression in FLCs transformed with MLL-AF9. Stat3bTG expression was induced via stimulation with IFNb. (C) in vitro proliferation was analyzed via growth curves
and cell cycle analysis by flow cytometry. Data, indicating 3 independent experiments carried out in triplicates, were compared using the Student t test, and differences were
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Crossbreeding and pIpC treatment gave rise to MxCre:PtenD/1,
MxCre:PtenD/1:Stat3bTG, MxCre:PtenD/D, and MxCre:PtenD/D:
Stat3bTG mice (MxCre is omitted in the annotation of mice
hereafter). All mice with a homozygous ablation of Pten included
in this study developed fatal myeloid leukemia within 110 days.
Strikingly, we observed a significant increase in disease latency
upon Stat3bTG expression in PtenD/D mice (Figure 3A). We
detected elevated numbers of myeloid (CD11b1Gr-11) cells in
the BM and spleen of terminally ill PtenD/D and PtenD/DStat3bTG
mice compared with PtenD/1 control animals, consistent with an
AML phenotype (supplemental Figure 3A). Although WBC count
was strongly increased upon homozygous deletion of Pten,
PtenD/DStat3bTG mice exhibited a WBC count similar to that of
healthy PtenD/1 controls (supplemental Figure 3B).
To address the effect of STAT3b on leukemia progression, we
analyzed mice at 3 different time points after pIpC injection: days
10, 20, and 30. We focused on the myeloid lineage as well as on
HSPCs (defined as Lin2Sca-11c-Kit1 [LSK]). Compared with
PtenD/1 control mice, PtenD/D mice already exhibited an increase of
myeloid cells in BM and spleen at day 10, which was delayed upon
Stat3bTG expression (Figure 3B top). Although the number of
HSPCs in the BM remained relatively unchanged, Pten deletion
caused a significant accumulation of HSPCs in the spleen, which
was less pronounced in PtenD/DStat3bTG mice (Figure 3B bottom).
Analysis of H&E-stained tissue sections from day 20 revealed
reduced leukemic infiltration in liver and spleen of PtenD/DStat3bTG
compared with PtenD/D mice (Figure 3C). Taken together, our data
indicate that increased STAT3b levels impair leukemia progression
and prolong disease latency in a Pten deletion–based AML
mouse model.
Stat3bTG expression impairs colony formation
capacity of MLL-AF9–transformed cells
The human fusion oncogene MLL-AF9 represents another widely
used model for functional studies of AML.51,52 We harvested
FLCs and BMCs from Stat3bTG and wt mice and transduced
them with a retrovirus encoding for MLL-AF9, coupled to the
fluorescent protein Venus (Figure 4A). Before BM isolation, mice
were treated with pIpC to induce Stat3bTG expression, whereas
FLCs were treated with interferon b (IFNb) in vitro to activate the
Mx1 promoter and express ectopic STAT3b (Figure 4B). As
a control, all wt mice and FLCs were similarly treated with pIpC
or IFNb, respectively. Of note, expression of total and phos-
phorylated STAT3a seemed unaffected by the expression of
Stat3bTG (Figure 4B). Homogeneous Venus1 cell populations
were used for all further in vitro experiments (supplemental
Figure 4A). Proliferation kinetics of MLL-AF9–transformed cells
were not altered between Stat3bTG and wt cells (Figure 4C).
Furthermore, mRNA levels of prominent STAT3a-regulated
genes involved in cell proliferation remained unchanged in
Venus1 Stat3bTG and wt FLCs (supplemental Figure 4B).
However, in methylcellulose-based colony formation assays,
the expression of Stat3bTG led to significantly reduced numbers
of colonies for BMCs as well as FLCs (Figure 4D left) upon serial
replating (supplemental Figure 4C). In addition, colony sizes
were slightly reduced in Stat3bTG cells (Figure 4D right).
Altogether, this indicates that Stat3bTG expression has no effect
on STAT3a activity or proliferation but impairs the cellular
capacity for self-renewal, colony formation, and tumorigenicity of
MLL-AF9–transformed cells.
STAT3b has a tumor-suppressive effect in an
MLL-AF9–dependent AML model
MLL-AF9–transformed Stat3bTG and wt FLCs were compared in
an in vivo transplantation AML model. Transduced cells were
injected into immunocompromised NOD.Cg-PrkdcscidIl2rgtm1Wjl/
SzJ (NSG) mice, and 4 weeks later, mice were treated with pIpC
to induce Stat3bTG expression. We confirmed Stat3bTG expres-
sion and phosphorylation with a FLAG-specific antibody and
western blot (supplemental Figure 5A-B). Additionally, we in-
vestigated the mRNA expression of total Stat3 and both
alternatively spliced isoforms (supplemental Figure 5C). Taken
together, these data confirm the increased expression of STAT3b
resulting from the transgene in vivo posttransplantation and
furthermore demonstrate the unaffected expression and activation
of STAT3a. As observed in the Pten model, transgenic Stat3b
expression caused an increase in survival of mice in comparison
with mice receiving wt cells in the MLL-AF9 model (Figure 5A).
Immunophenotyping of Venus1 blasts in PB and BM revealed
high expression levels of the myeloid marker CD11b together
with low to intermediate expression levels of c-kit (supplemental
Figure 5D). Clear signs of leukemic infiltration in liver, spleen, and
PB were found in both experimental groups at the time of
euthanasia (supplemental Figure 6A).
To investigate the effect of STAT3b on MLL-AF9–driven leukemia
progression, we analyzed mice 6 weeks posttransplantation.
Here, the delayed disease phenotype in Stat3bTG mice was
evident in direct comparison; WBC count and relative spleen
weight and size were reduced in the Stat3bTG group (Figure 5B).
Numbers of myeloid Venus1 blasts were notably lower in PB,
BM, and spleen of Stat3bTG mice (Figure 5C). H&E-stained
tissue sections demonstrated significantly decreased infiltra-
tion in liver and spleen and diminished numbers of blasts in PB
smears (Figure 5D). In accordance with our previous observa-
tions, these results show that the elevated expression of
STAT3b delays disease progression and the leukemic infiltration
of peripheral hematopoietic organs, explaining the demonstrated
survival advantage in Stat3bTG mice.
Next, we addressed proliferation and apoptosis in the MLL-
AF9–dependent AML model. Neither in quantification of Ki671
cells (supplemental Figure 6B) nor in cell cycle analysis of
Venus1 spleen-derived blasts did we observe a significant
difference in proliferation (supplemental Figure 6C). Spleen and
liver sections stained for cleaved caspase 3 demonstrated
similarly low levels of apoptosis in both groups (supplemen-
tal Figure 6D), which was confirmed by annexin V staining of
Figure 4. (continued) found not to be statistically significant. (D) Methylcellulose-based colony formation assays were analyzed by number of colonies upon 4 replatings
(1 replating shown; n 5 12 per group). Representative pictures of BMC colonies are shown. Data, indicating 2 independent experiments, were compared using the Student
t test. **P , .01, ****P , .0001. NSG, NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ.
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Figure 5. STAT3b prolongs survival and has a tumor-suppressive effect in MLL-AF9–dependent AML 6 weeks posttransplantation. (A) Kaplan-Meier plot of
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice receiving transplants of Stat3bTG and wt FLCs (n 5 15 per group), showing significantly different survival (P 5 .0087). (B) WBC
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blasts derived from PB, BM, liver, and spleen (supplemental
Figure 6E). Thus, the antitumorigenic function of STAT3b seems
to be independent of the direct regulation of apoptosis or
proliferation.
Gene expression patterns of migratory target genes
change upon increased STAT3b expression
To identify Stat3bTG-induced global changes in gene expression in
MLL-AF9–driven leukemia, we performed RNA sequencing of
sorted Venus1 BMCs harvested from mice 6 weeks posttrans-
plantation. We analyzed 3 animals per group and found 70
genes that were significantly up- (32 genes) or downregulated
(38 genes) upon Stat3bTG expression (Figure 6A). Gene set
enrichment analysis revealed enriched expression of genes
in the interleukin 6 (IL6)/JAK/STAT3 signaling pathway in
Stat3bTG blasts (supplemental Figure 7A). Furthermore, genes
allocated to Reactome pathways of cell surface interactions at
the vascular wall were significantly upregulated, including Sell,
Itgax, and Cd177 (supplemental Figure 7B). The surface
molecule SELL (L-SELECTIN, CD62L) represents an interest-
ing target due to its role in lymphocyte migration through
vasculature, because a downregulation of SELL on lympho-
cytes or leukemic blasts can initiate cell migration from the BM
into the PB, where it is shed.53-56 Expression of Sell was
significantly upregulated in Stat3bTG blasts at the mRNA level
(Figure 6B top). We confirmed the Stat3bTG-specific upregu-
lation of SELL in vivo on BM-derived Venus1 blasts via flow
cytometry (Figure 6B middle). Additionally, we measured
soluble, shed SELL in the plasma and detected decreased
levels in mice receiving Stat3bTG cell transplants (Figure 6B
bottom), indicating that Stat3bTG blasts migrate in lower
numbers in comparison with wt. This is in accordance with
our in vivo findings, which demonstrated a significantly reduced
organ infiltration and blast count in the PB of the Stat3bTG
group. Lastly, we repeated the methylcellulose-based colony
formation assays with BMCs and FLCs that were previously
treated with a blocking antibody for cell surface–bound SELL/
CD62L. Indeed, the antibody-mediated blocking of SELL
reversed the effect of Stat3bTG expression (Figure 6C) upon
serial replating (supplemental Figure 7C). As a control, we
analyzed the blocking efficiency via flow cytometry (supple-
mental Figure 7D). In addition, we used publicly available data
to identify STAT3-specific binding motifs in the Sell promoter
(supplemental Figure 8A). Analysis of published chromatin
immunoprecipitation sequencing data sets from human and
mouse samples confirmed multiple STAT3 binding events in
regions across the gene (supplemental Figure 8B). In summary,
these data show that STAT3b can promote target gene
induction and actively influence the expression of cell surface
markers in MLL-AF9–expressing blasts involved in vascular
interaction and migration. Among those markers, SELL might
play a distinct role in the antitumorigenic effect of Stat3bTG in
AML cells.
Increased levels of SELL correlate with favorable
clinical prognosis and increased event-free survival in
AML patients
Finally, we investigated SELL expression in our AML cohort of
favorable, intermediate, and adverse prognostic groups and found
elevated mRNA levels of SELL in patients with a favorable
prognosis, which was associated with a higher STAT3b/a mRNA
ratio (Figure 7A). Accordingly, we also found elevated levels of
SELL/CD62L in samples derived from patients with a favorable
prognosis measured via flow cytometry (Figure 7B). Using 3 of the
identified STAT3b-regulated gene targets involved in cell migration
(SELL, ITGAX,CD177) as a STAT3b gene signature and a publicly
available AML patient data set (n 5 740), we were able to show an
association between high expression of the STAT3b signature and
prolonged event-free survival (HR, 0.78; P 5 .033; Figure 7C). In
conclusion, these data suggest that STAT3b-dependent elevated
SELL expression correlates with a favorable outcome in AML
patients.
Discussion
STAT3 is frequently found to be constitutively active in AML.25-27
We were able to demonstrate a low STAT3b/a mRNA ratio in
AML cells in comparison with healthy HSPCs as well as a high
STAT3b/a mRNA ratio in patients with a favorable cytoge-
netic prognosis. Moreover, a lower STAT3b/a mRNA ratio was
associated with higher overall mortality. Notably, this relationship
persists despite correction for established prognostic factors,
such as cytogenetic risk category, age, and percentage of blasts
at diagnosis. Although these results need to be verified in larger
confirmatory studies, they are especially plausible in light of
the mechanistic insight gained from our animal experiments,
pointing to a central role of STAT3b in AML. Intriguingly, findings
are similar to the described STAT3b function in esophageal
squamous cell carcinoma patients, where it was established as
a protective prognostic marker.17
Here, we describe a novel tumor-suppressive role for STAT3b in
AML. Evidence was provided from an inducible Stat3b trans-
genic mouse model in combination with 2 independent dri-
vers for AML, either MLL-AF9 expression or PTEN deficiency.
We demonstrated that Stat3bTG expression in AML blasts
significantly extended survival by delaying infiltration of PB
and hematopoietic organs, which is characteristic for AML.
Our data further suggest that the antitumorigenic effect of
STAT3b depends on the tumor-intrinsic regulation of a small set
of significantly regulated genes. Several genes of the IL6/JAK/
STAT3 signaling pathway and the Reactome pathway for
cell surface interactions at the vascular wall were upregulated
in Stat3bTG blasts, demonstrating that STAT3b can actively
regulate gene expression.11,13-16 SELL was identified as a tar-
get gene of interest, because it was shown to be specifi-
cally upregulated in Stat3bTG blasts and is known to be
expressed in newly diagnosed AML patients.57-61 In particular,
Figure 5. (continued) count and relative spleen weight and size. (C) Quantification by flow cytometry of myeloid Venus1 blasts in PB, BM, and spleen of Stat3bTG and wt
mice. (D) H&E-stained liver and spleen sections and PB smears of wt and Stat3bTG animals. Quantifications shown as infiltrate area/total organ area (%) and number of blasts/
total cell number (%). (B-D) Data were compared using the Student t test. *P , .05, **P , .01.
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Figure 6. Gene expression patterns upon increased STAT3b expression reveal SELL to be a potential STAT3b target. (A) Heatmap showing significantly up-
(32 genes) or downregulated (38 genes) genes between murine wt and Stat3bTG BM-derived Venus1 blasts (n 5 3). (B) Normalized mRNA expression, displaying the
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SELL is important for the homing of AML cells, because its
downregulation could initiate the mobilization of AML blasts from
the BM into the PB, where it is shed and remains in the PB in its
soluble form.53-56 In our MLL-AF9–based AML in vivo model,
SELL was specifically upregulated in Stat3bTG BM–resident
AML blasts at the mRNA and protein levels in comparison with
wt. This explains the delayed peripheral infiltration of Stat3bTG
blasts and the consequent suspension of disease progression. In
line with this, levels of shed SELL in the PB were significantly
reduced in mice receiving Stat3bTG cells, indicating a clear
reduction in AML cell mobilization.
SELL expression on hematopoietic progenitors in vitro has been
described to correlate with their clonogenic potential.62 Like-
wise, we found the capacity of transformed BMCs and FLCs
for in vitro colony formation to be impaired upon Stat3bTG
expression, which was preventable with antibody-mediated
blocking of SELL. Together, these findings indicate that the
antitumorigenic effect of Stat3bTG expression in AML cells might
be at least partially dependent on the upregulation of SELL.
However, because the colony formation capacity of HSPCs and
AML cells considerably depends on STAT3 activity,28,63
STAT3b might also counteract STAT3 and therefore reduce
colony formation. Because of its unique C-terminus, STAT3b
homodimers have been demonstrated to exhibit prolonged
phosphorylation and nuclear retention64 as well as enhanced
DNA-binding affinity16,65 and dimer stability.65 Thus, STAT3b
can directly compete with STAT3a and furthermore regu-
late STAT3a via the formation of heterodimers.15,17 Neverthe-
less, we failed to obtain any evidence suggesting a negative
regulation of STAT3a by STAT3b in AML. In fact, we found the
activity of STAT3a and STAT3a-regulated genes in AML blasts
to be unaffected by the expression of Stat3bTG, which is similar
to previous findings.11
In AML patients, increased SELL expression was reported to
correlate with good-risk karyotypes.66 Accordingly, we found
SELL levels to be significantly elevated in patients with a favorable
prognosis, in contrast to patients with an adverse prognosis.
Furthermore, analysis of publicly available AML data sets revealed
a correlation between high expressions of newly identified
STAT3b-regulated migratory genes (SELL, ITGAX, CD177) and
superior event-free survival. In addition to Sell, Itgax, and CD177,
we identified other novel STAT3b-regulated genes, such as Lif,
Sox12, Mafb, and Ifnlr1, that might also contribute to the tumor-
suppressive effect of STAT3b but whose specific role in AML
remains elusive. Taken together, the exact mechanism underlying
the tumor-suppressive function of STAT3b is most likely a combi-
nation of various regulated genes, such as Sell, and deserves
further investigation.
In summary, our study unequivocally demonstrates that STAT3b
acts as a tumor suppressor in AML and specifically regulates gene
expression in AML blasts, impairing leukemia progression and
extending survival.
Figure 6. (continued) upregulation of Sell in Venus1 Stat3bTG blasts, is shown (top; n 5 3 per group). Quantification of cell surface–bound SELL/CD62L in BM-derived
Venus1 blasts, measured by flow cytometry (middle; n 5 6 per group), and levels of soluble, shed SELL in plasma, assessed via enzyme-linked immunosorbent assay (bottom;
n 5 9 per group), demonstrate the upregulation of SELL on the cell surface of Stat3bTG blasts and the difference in shed SELL present in PB. Data were compared using
the Student t test. (C) Methylcellulose-based colony formation assays of wt and Stat3bTG FLCs and BMCs, pretreated with or without a blocking antibody for SELL/CD62L
(MEL-14), were analyzed by number of colonies upon 3 replatings (1 replating shown; n 5 12 per group). Data were compared using 1-way analysis of variance. *P , .05,
**P , .01, ***P , .001.
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Figure 7. Increased levels of SELL correlate with favorable clinical
prognosis in our AML cohort and increased event-free survival in publicly
available AML patient data sets. (A) SELL mRNA expression levels (normalized
to b-ACTIN) in AML patients with favorable (n 5 9), intermediate (n 5 38), or adverse
(n 5 8) prognosis. Data (favorable vs adverse) were compared using the Student t test.
(B) SELL/CD62L expression levels analyzed by flow cytometry in AML blasts from
patients with favorable (n 5 7), intermediate (n 5 38), or adverse (n 5 7) prognosis.
Data (favorable vs adverse) were compared using the Student t test, and significance is
indicated by P 5 .058. (C) Gene signatures from publicly available AML patient data
sets (n 5 740) were compared, showing that patients with high expression of the
STAT3b signature (SELL, ITGAX, CD177) had better survival compared with patients
with low expression in 740 AML patients (HR, 0.78; P 5 .33). *P , .05.
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